Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 02 Jun 2026 for Ascendis Pharma A/S, €19k. Read the official filing
Filing timeline
BuySaleScott Thomas Smith
Insider track record
Disclosed buys
2
Disclosed sells
0
Signal history
Closed purchases
Market purchases
2
Positive at T+90
100%
Median T+90
+20.7%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +20.0%Entry US$216.79 · Close at T+90 US$260.25
- +21.4%Entry US$216.60 · Close at T+90 US$263.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Scott Thomas Smith: trading record in brief
Scott Thomas Smith discloses dealings in Ascendis Pharma A/S to SEC (Form 4). The record holds 2 filings, for trades running from 29 May 2026 to 2 June 2026.
No open-market sale appears; the market trades are 2 purchases worth €67k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
On 2 June 2026 came the latest disclosure, an open-market purchase for €19k in Ascendis Pharma A/S. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Scott Thomas Smith
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
100 shares@ US$219.0028.2% of flowOrdinary SharesSEC:0001610717-26-000179:0
Canonical exit: 31 Aug 2026 (T+90)
250 shares@ US$223.3271.8% of flowOrdinary SharesSEC:0001610717-26-000176:0
Canonical exit: 27 Aug 2026 (T+90)
2 of 2 declarations
